Hong Kong firm petitions FDA on acetaminophen equivalency
This article was originally published in The Tan Sheet
Executive SummaryWishing to bring its "effective, safe but cheap drug to U.S. patients," Bright Future Pharmaceutical Lab Ltd. asks FDA to allow the use of GlaxoSmithKline's 500-mg acetaminophen drug Panadol as the reference listed drug in an abbreviated new drug application for the Hong Kong firm's BF-PARADAC. Although the Orange Book contains no RLD identical to BF-PARADAC in dosage form, strength or formulation, Panadol is pharmaceutically and/or therapeutically equivalent to Bright Future's drug, the company says in its ANDA suitability 1petition dated Dec. 17. Bright Future says the bioequivalence study of BF-PARADAC using Panadol as the reference is complete, and asks FDA to suggest another RLD equivalent to its drug
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.